Phathom Pharmaceuticals Inc
PHAT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$533.13M
Close$
$-4.09
165.2% downside
Current Fair Value
165.2% downsideOvervalued by 165.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $533.13 Million |
|---|---|
| Enterprise Value | $516.52 Million |
| Earnings per Share | $-3.03 |
| Beta | 0.5 |
| Outstanding Shares | 84,892,631 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | 58.00% |
| Return on Invested Capital | 176.57% |
Valuation & Multiples
| P/E Ratio | -5.1 |
|---|---|
| PEG | - |
| Price to Sales | 2.09 |
| Price to Book Ratio | -1.26 |
| Enterprise Value to Revenue | 1.88 |
| Enterprise Value to EBIT | 1.72 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS
-$0.16
Est. -$0.11Revenue
$84.72 M
Est. $84.82 MNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
-$0.07
Consensus analyst estimateRevenue Estimate
$97.73 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 13.51% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.16%▼ 68.41% |
|---|---|
| Total Invested | $111.04M▼ 85.88% |
| Investors Holding | 30▼ 143.00% |
About Phathom Pharmaceuticals Inc
55 employees
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...